TCR engineered T cells recognise intracellular targets that are presented as immunogenic peptides by MHC molecules; however, many tumours can escape immune recognition by downregulating MHC molecules, thus making them undetectable even by primed T cells. Here, HLA-C is linked to neoplasm.